Asian Growth Leaders With High Insider Ownership In July 2025
Top 10 Growth Companies With High Insider Ownership In Asia
Name
Insider Ownership
Earnings Growth
Vuno (KOSDAQ:A338220)
15.6%
109.8%
Techwing (KOSDAQ:A089030)
18.8%
68%
Suzhou Sunmun Technology (SZSE:300522)
35.4%
77.7%
Sineng ElectricLtd (SZSE:300827)
36%
25.8%
Shanghai Huace Navigation Technology (SZSE:300627)
24.3%
23.5%
Samyang Foods (KOSE:A003230)
11.7%
26.5%
Novoray (SHSE:688300)
23.6%
28.2%
M31 Technology (TPEX:6643)
30.8%
63.4%
Laopu Gold (SEHK:6181)
35.5%
42.3%
Fulin Precision (SZSE:300432)
13.6%
43.7%
Click here to see the full list of 597 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.
Let's take a closer look at a couple of our picks from the screened companies.
Kingsoft
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Kingsoft Corporation Limited operates in the entertainment and office software sectors across Mainland China, Hong Kong, and internationally, with a market cap of HK$49.03 billion.
Operations: The company's revenue segments include Online Games and Others, generating CN¥5.32 billion, and Office Software and Services, contributing CN¥5.20 billion.
Insider Ownership: 19.1%
Kingsoft is trading significantly below its estimated fair value, presenting a potential opportunity for investors. Despite slower revenue growth forecasts of 13.3% per year compared to the 20% benchmark, earnings are expected to grow at a robust 22.3% annually, outpacing the Hong Kong market average. Recent earnings show stable performance with Q1 revenue reaching CNY 2.34 billion and net income remaining steady year-over-year at CNY 283.87 million, indicating consistent operational execution amid growth prospects.
Dive into the specifics of Kingsoft here with our thorough growth forecast report.
Our expertly prepared valuation report Kingsoft implies its share price may be lower than expected.
Henan Shijia Photons Technology
Simply Wall St Growth Rating: ★★★★★★
Overview: Henan Shijia Photons Technology Co., Ltd. operates in the photonics industry, focusing on the development and manufacturing of advanced optical components, with a market cap of CN¥21.25 billion.
Operations: The company's revenue is primarily derived from its Optical Networking Equipments segment, generating CN¥1.31 billion.
Insider Ownership: 10.1%
Henan Shijia Photons Technology has shown strong growth, with Q1 2025 sales reaching CNY 436.21 million, more than doubling from the previous year. Net income also rose significantly to CNY 93.19 million. Forecasts suggest revenue and earnings will grow faster than the Chinese market at 28% and over 40% annually, respectively. Despite high volatility in its share price recently, the company maintains a solid return on equity forecast of 26.6%, highlighting robust financial health amidst high insider ownership levels.
Click here and access our complete growth analysis report to understand the dynamics of Henan Shijia Photons Technology.
Our valuation report here indicates Henan Shijia Photons Technology may be overvalued.
Orbbec
Simply Wall St Growth Rating: ★★★★★☆
Overview: Orbbec Inc. designs, manufactures, and sells 3D vision sensors with a market cap of CN¥26.66 billion.
Operations: Orbbec generates revenue through its design, manufacturing, and sale of 3D vision sensors.
Insider Ownership: 36.4%
Orbbec has demonstrated significant growth, with Q1 2025 sales reaching CNY 191.06 million, more than doubling from the previous year. The company turned a net loss into a net income of CNY 24.32 million. Revenue is forecast to grow at an impressive 34.3% annually, outpacing the Chinese market's average growth rate of 12.4%. Despite its low return on equity forecast of 8.9%, Orbbec's high insider ownership aligns with its strong revenue trajectory and recent private placement activity.
Click to explore a detailed breakdown of our findings in Orbbec's earnings growth report.
Our comprehensive valuation report raises the possibility that Orbbec is priced higher than what may be justified by its financials.
Where To Now?
Gain an insight into the universe of 597 Fast Growing Asian Companies With High Insider Ownership by clicking here.
Want To Explore Some Alternatives? These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SEHK:3888 SHSE:688313 and SHSE:688322.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Novo Nordisk lowers sales and operating profit outlook for 2025
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and operating profit outlook at CER. In the first six months of 2025, Novo Nordisk's sales increased by 18% and operating profit increased by 29%, both at CER. Sales growth in the first six months of 2025 was positively impacted by gross-to-net sales adjustments related to prior years, including an adjustment related to the 340B provision of around DKK 3 billion in the second quarter of 2025. Operating profit growth is positively impacted by the ocedurenone impairment in the second quarter of 2024, partially countered by impacts related to the acquisition of the three Catalent manufacturing sites. Profit and loss Second quarter 2025 First six months 2025 Sales growth (CER) 18% 18% Operating profit growth (EBIT) (CER) 40% 29% Diluted earnings per share (in DKK) 5.96 12.49 Novo Nordisk has updated the full-year outlook for 2025, with sales growth now expected to be 8-14% and operating profit growth expected to be 10-16%, both at CER. Sales and operating profit growth reported in Danish kroner is now expected to be 4 and 7 percentage points lower than at CER, respectively, primarily due to depreciation of the USD/DKK exchange rate1. Outlook 2025 (CER) Expectations 29 July Expectations 7 May Sales growth 8-14% 13-21% Operating profit growth (EBIT) 10-16% 16-24% The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025. This is related to lower growth expectations for Wegovy® in the US obesity market, lower growth expectations for Ozempic® in the US GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy® in select IO markets. For Wegovy® in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition. Despite the expiry of the FDA grace period for mass compounding on 22 May 2025, Novo Nordisk market research shows that unsafe and unlawful mass compounding has continued, and that multiple entities continue to market and sell compounded GLP-1s under the false guise of 'personalisation'. Novo Nordisk is pursuing multiple strategies, including litigation, to protect patients from knockoff 'semaglutide' drugs. Novo Nordisk is deeply concerned that, without aggressive intervention by federal and state regulators and law enforcement, patients will continue to be exposed to the significant risks posed by knockoff 'semaglutide' drugs made with illicit or inauthentic foreign active pharmaceutical ingredients. As unsafe and unlawful mass compounding continues, the Wegovy® penetration within the cash channel has been lower-than-expected. Within this channel, NovoCare® Pharmacy was launched in March 2025. Wegovy® prescriptions via NovoCare® Pharmacy (including TeleHealth collaborations) amount to around 11,000 total weekly prescriptions, in addition to around 20,000 weekly prescriptions in the retail cash channel. Novo Nordisk will continue to invest in the expansion of direct-to-patient initiatives such as NovoCare® Pharmacy and further collaborations with telehealth organisations. Within the insured channel, despite the initiation of new commercial activities of Wegovy® in the first half of 2025, the sales outlook also reflects lower-than-expected penetration for Wegovy®, mainly due to slower market expansion and competition. Novo Nordisk continues to engage in additional commercial initiatives and expects a regulatory decision around the Wegovy® MASH indication during the second half of 2025. Moreover, Novo Nordisk continues to expect a positive contribution from changes to the CVS national template formulary effective 1 July 2025, where Wegovy® is now the only GLP-1 medicine covered for obesity. For Ozempic®, the updated outlook is negatively impacted by competition in the US. Novo Nordisk continues to invest in commercial activities and label updates towards driving further market penetration of Ozempic®. Finally, while IO Wegovy® sales are growing at high rates and launches are progressing, the sales outlook reflects lower-than-expected penetration for Wegovy® in select IO markets due to slower market expansion and competition. With around 1 billion people living with obesity globally and only a few million on treatment, the outlook reflects a continued global rollout of Wegovy® to more markets. The updated expectation for operating profit growth reflects the lower sales growth outlook, partially countered by reduced spending. A negative mid-single-digit operating profit growth impact related to the acquisition of the three former Catalent manufacturing sites remains included in the guidance. Novo Nordisk now expects financial items (net) for 2025 to amount to a gain of around DKK 3 billion. This is mainly driven by expected gains on hedged currencies, primarily the US dollar, partially offset by interest expenses related to funding of the debt-financed Catalent transaction. Finally, the free cash flow is now expected to be DKK 35-45 billion, reflecting the lower-than-planned expected sales growth, mainly driven by lower volume growth of GLP-1-based treatments in the US and related cash flow implications amplified by the US gross-to-net system. Novo Nordisk's full disclosure of the financial results for the first six months of 2025 will be published on 6 August 2025, where more information will be available. The above expectations are based on additional assumptions, including assumptions described on pages 14 and 15 of the Financial report for the first three months of 2025 (Company Announcement No 14/2025). The forward-looking statements on page 23 in the Financial report for the first three months of 2025 (Company Announcement No 14/2025) also apply to this company announcement. Conference call Novo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode +45 3075 5956 jrde@ Sina Meyer +45 3079 6656 azey@ Max Ung +45 3077 6414 mxun@ Frederik Taylor Pitter (US)+1 609 613 0568 fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 1 Based on exchange rates of 23 July 2025 with e.g. a USD/DKK spot rate of 635. Full currency overview to be released as part of Novo Nordisk's full disclosure of the financial results on 6 August 2025 Company announcement No 18 / 2025 Attachment CA250729-Q2-Financial-OutlookError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Cadence to pay $140m fine for illegal tech exports to China
The US Department of Justice (DOJ) announced that Cadence Design Systems has agreed to plead guilty and pay more than $140m in penalties for exporting semiconductor design tools to a Chinese military university. The company based in San Jose, California, will pay nearly $118m in criminal penalties. This follows its admission of violating export controls by selling electronic design automation (EDA) technology to the National University of Defense Technology (NUDT), which is associated with China's Central Military Commission. National Security Assistant Attorney General John Eisenberg said: 'Cadence has agreed to accept responsibility for unlawfully exporting sensitive semiconductor design tools to a restricted Chinese military university and has implemented a strong export compliance programme to help prevent any further illegal transmission of American technology. 'American ingenuity is one of our Nation's most precious assets, and the National Security Division will vigorously enforce US export control laws to protect the technological advantage we enjoy because of that ingenuity.' NUDT, added to the US Department of Commerce's Entity List in 2015, is believed to have used US-origin components to develop supercomputers for military purposes. From February 2015 to April 2021, Cadence and its subsidiary in China exported EDA tools without obtaining necessary licences, despite knowing NUDT's status on the Entity List. Cadence's court documents reveal employees facilitated exports to NUDT through Central South CAD Center (CSCC), an alias for the Chinese university. The company continued transactions until September 2020 when it ended its relationship with CSCC due to its ties with NUDT. The US Bureau of Industry and Security (BIS) also announced a parallel civil enforcement settlement, with Cadence agreeing to pay over $95m in civil penalties. Further investigation revealed that employees concealed exports' true destination from Cadence's compliance personnel, said the DOJ. The employees also used aliases in communications to avoid detection. Additionally, Cadence transferred contracts from CSCC to Phytium Technology, another entity linked with NUDT. This was before placing Phytium on export hold in March 2021. Following the DOJ and BIS crediting Cadence's payments under the coordinated agreements, the company will pay a total of over $140m in combined net criminal and civil penalties and forfeiture. The resolution awaits approval from a federal judge in the Northern District of California. The Federal Bureau of Investigation and BIS's Office of Export Enforcement conducted investigations into the case. "Cadence to pay $140m fine for illegal tech exports to China" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
LG Innotek to take stake in lidar maker Aeva as part of $50 million deal
By Stephen Nellis SAN FRANCISCO (Reuters) -Aeva Technologies said on Tuesday that South Korean camera module maker LG Innotek will take an equity stake in Aeva as part of a $50 million strategic collaboration. Aeva makes lidar sensors that help vehicles and industrial equipment gain a detailed three-dimensional view of their environment and detect how fast surrounding objects are moving. It supplies sensors to vehicle firms such as Daimler Truck and industrial equipment makers such as Nikon. As part of the deal, LG Innotek will make a $32 million equity investment in Aeva for a "single-digit percentage ownership" in the company, Aeva CEO Soroush Salehian told Reuters in an interview. The remainder of the deal will go toward building production capacity for sensors that can go into robotics and consumer devices, in addition to Aeva's existing markets of vehicles and industrial equipment. 'The ultimate goal of this partnership is for LG Innotek and Aeva to grow together as key players leading the next-generation lidar market through a long-term technology partnership that goes beyond the supply of products,' the South Korean electronics supplier's CEO, Hyuksoo Moon, said in a statement. Salehian told Reuters that Aeva is working to integrate its entire sensor into a single chip whose price can be driven low enough to make it viable in consumer electronics such as augmented reality headsets. "The roadmap that we're going towards is double-digit dollars," Salehian told Reuters. "We are already working towards the next generation that will allow for a very low-cost solution, which we think will be a game changer for mass adoption of what we call precision sensing."
